Hoffmann-la Roche Inc.

Pfizer Corporation

Daiichi Sankyo Company, Limited

Dirk Ponsel

Sandra Miller

Tohru Takahashi

Hans-Willi Krell

Jens Niewoehner

Eisuke Tsuda

Robert Rauchenberger

Gregory John Carven

Hendrik Knoetgen

Yoshiharu Hiruma

Toshinori Agatsuma

Toshiaki Ohtsuka

Tatsuji Matsuoka

Ichiro Watanabe

Ingrid Schuster

Robert Arch

Ulrike Schubert

Shinji Ogawa

Jun Kuai

Lydia Mosyak

Robert Mühlbacher

Kathrin-Ladetzki Baehs

Steffen Runz

Engin Toksoez

The present invention provides antibodies, or antigen-binding fragment thereof, which specifically bind to PDGF-B. The invention further provides a method of obtaining such antibodies and nucleic acids encoding the same. The invention further relates to compositions and therapeutic methods for use of these antibodies for the treatment and/or prevention of PDGF-B mediated diseases, disorders or conditions.

Platelet-derived growth factor B specific antibodies and compositions and uses thereof

An isolated antibody capable of binding Siglec-15 which inhibits osteoclast formation and/or osteoclastic bone resorption, or a functional fragment thereof. The heavy chain of the antibody comprises a CDRH1 comprising a sequence having at least 80% sequence identity to SEQ ID NO: 106, a CDRH2 comprising a sequence having at least 80% sequence identity to SEQ ID NO: 107, and a CDRH3 comprising a sequence having at least 80% sequence identity to one of SEQ ID NOS: 35, 45, 55, 65 or 80. The light chain of the antibody comprises a CDRL1 comprising a sequence having at least 80% sequence identity to SEQ ID NO: 73 or 83, a CDRL2 comprising a sequence having at least 80% sequence identity to SEQ ID NO: 108, and a CDRL3 comprising a sequence having at least 80% sequence identity to one of SEQ ID NOS: 40, 50, 60, 70, 90, 100 or 109.

Antibody targeting osteoclast-related protein Siglec-15

Disclosed herein are methods for the recombinant expression of mammalian cell membrane-bound human CCN1 or a CCN1 domain thereof in mammalian cells, comprising transforming a mammalian host cell with a vector encoding CCN1 or a CCN1 domain thereof C-terminally fused to a mammalian cell transmembrane domain (CCN1 fusion protein), expressing said CCN1 or CCN1 domain fusion protein in said host cell, and recovering said membrane bound CCN1 or said CCN1 domain thereof. Disclosed herein is the use of such membrane bound CCN1 and domain for the generation of corresponding antibodies. Antibodies against human CCN1 are useful for the treatment of diseases.

Antibodies against human CCN1 and uses thereof

Growing community of inventors

Germering, Germany

Dirk Ponsel